Get started
PHARMICELLPP

PHARMICELL

11,080KRWD
−490−4.24%
At close at 08:40 GMT
KRW
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

005690 fundamentals

Key facts

Market capitalization‪642.04 B‬KRW
Dividend yield (indicated)0.19%
Price to earnings Ratio (TTM)—
Basic EPS (TTM)108.64KRW
Founded1968
Employees (FY)—
CEOHyun-Soo Kim
Websitepharmicell.com
About

Pharmicell Co., Ltd. is engaged in the development of stem cell based pharmaceuticals and technologies. It operates through the Bio and Chemical Business Divisions. The Bio division provides cosmetics, cell for researches, medical testing equipment, and others. The Chemical division offers nucleoside, agricultural pesticides, fire retardant materials, and others. The company was founded on August 20, 1968 and is headquartered in Seoul, South Korea.

Ownership
‪‪60.00 M‬‬
Free Float shares
‪‪52.95 M‬‬ (88.24%)
Closely held shares
‪‪7.05 M‬‬ (11.76%)
Free Float shares
‪‪52.95 M‬‬ (88.24%)
Closely held shares
‪‪7.05 M‬‬ (11.76%)
Capital structure
Market cap
‪‪642.04 B‬‬
Enterprise value
‪‪642.04 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪642.04 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Valuation ratios
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪70.00‬
‪140.00‬
‪210.00‬
‪280.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−22%‬
‪−11%‬
‪0%‬
‪11%‬
‪22%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−8.00 B‬‬
‪0.00‬
‪‪8.00 B‬‬
‪‪16.00 B‬‬
‪‪24.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−22.00 B‬‬
‪‪−11.00 B‬‬
‪0.00‬
‪‪11.00 B‬‬
‪‪22.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−22.00 B‬‬
‪‪−11.00 B‬‬
‪0.00‬
‪‪11.00 B‬‬
‪‪22.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Biochemistry Division
Biomedical Division
By country
Period: 2024
South Korea
United States
Europe
Asia

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
2016
2022
2023
2024
2025
‪0.00‬
‪‪35.00 B‬‬
‪‪70.00 B‬‬
‪‪105.00 B‬‬
‪‪140.00 B‬‬
Actual
Estimate
Earnings
Next:Feb 25, 2026
2016
2022
2023
2024
2025
‪−200.00‬
‪0.00‬
‪200.00‬
‪400.00‬
‪600.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
18.41%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.19%
Last payment
20.00
Last ex-date
Dec 27, 2024
Dividend history
‪0.00%‬
‪0.07%‬
‪0.14%‬
‪0.21%‬
‪0.28%‬
2020
2021
2022
2023
2024
‪0.00‬
‪5.00‬
‪10.00‬
‪15.00‬
‪20.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−5.00 B‬‬
‪0.00‬
‪‪5.00 B‬‬
‪‪10.00 B‬‬
‪‪15.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
No data available
There's currently no assets and liabilities data to show.